行情

ARDX

ARDX

Ardelyx
NASDAQ

实时行情|Nasdaq Last Sale

7.14
-0.03
-0.42%
盘后: 7.14 0 0.00% 16:30 01/17 EST
开盘
7.23
昨收
7.17
最高
7.40
最低
7.12
成交量
46.70万
成交额
--
52周最高
8.49
52周最低
1.860
市值
5.92亿
市盈率(TTM)
-4.3362
分时
5日
1月
3月
1年
5年

分析师评级

5位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ARDX 新闻

  • How Ardelyx, Inc. (NASDAQ:ARDX) Can Impact Your Portfolio Volatility
  • Simply Wall St..2019/12/31 10:16
  • The Daily Biotech Pulse: Axovant Surges On Gene Therapy Study Results, FDA Approves Merck's Ebola Vaccine, Abeona Announces Offering
  • Benzinga.2019/12/20 13:12
  • The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission
  • Benzinga.2019/12/05 12:14
  • The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission
  • Benzinga.2019/12/05 12:14

更多

所属板块

生物技术和医学研究
-0.16%
制药与医学研究
+0.06%

热门股票

名称
价格
涨跌幅

ARDX 简况

Ardelyx, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutics focuses on addressing cardiorenal and gastrointestinal (GI) diseases. It operates through the research, development and commercialization of biopharmaceutical products segment. The Company's products line includes cardiorenal portfolio and gastrointestinal portfolio. The Company's cardiorenal portfolio includes two Phase III clinical product candidates, tenapanor in Phase III clinical development for treating hyperphosphatemia in end-stage renal disease (ESRD) patients on dialysis and RDX7675 in Phase III clinical development for treating hyperkalemia in chronic kidney disease (CKD) and heart failure patients. The cardiorenal portfolio includes tenapanor, RDX7675, RDX013 and RDX011. Its gastrointestinal portfolio is led by tenapanor for the treatment of irritable bowel syndrome with constipation (IBS-C). The gastrointestinal portfolio includes tenapanor, RDX8940, RDX011 and RDX023.
展开

Webull提供Ardelyx Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。